Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
28 Results for "
DCC
" in MedChemExpress (MCE) Product Catalog:
Products (28)
28 Results for "DCC" in MCE Product Catalog:
13
13 Publications Verification
Synonyms: DCC-2036
Rebastinib (DCC-2036) is an orally active, non-ATP-competitive Bcr-Abl inhibitor, with IC50 values of 0.8 nM and 4 nM against Abl1 WT and Abl1 T315I, respectively. Rebastinib potently inhibits CYP2C8 (IC50 = 0.0533 μM) and CYP2C9 (IC50 = 2.54 μM). Rebastinib allosterically inhibits Tie2 with an IC50 of 0.63 nM. Rebastinib inhibits the transcriptional activity of FoxO1. Rebastinib inhibits SRC family kinases, KDR and FLT3 kinases. Rebastinib induces Apoptosis. Rebastinib exerts anti-tumor activity in breast cancer. Rebastinib exerts anti-angiogenic effects. Rebastinib increases myotube diameter and improves reduced contractility. Rebastinib can be used in research related to triple-negative breast cancer, luminal breast cancer, pancreatic neuroendocrine tumors, muscle atrophy, cancer cachexia, chronic myeloid leukemia, and B-lymphocytic leukemia .
8
8 Cited Publications
Synonyms: DCC-2618
Ripretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFRA switch-control inhibitor. Ripretinib (DCC-2618) targets and binds to both wild-type and mutant forms of KIT and PDGFRA specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. Ripretinib (DCC-2618) also inhibits multiple other kinase targets, such as FLT3 and KDR (or VEGFR-2) . DCC-2618 exerts antineoplastic effect and induces apoptosis .
2
2
2 Cited Publications
Art. -Nr.: HY-160699
CAS. Nr.: 2543673-19-2
DCC-3116 is an orally active ULK1/2 inhibitor. DCC-3116 can inhibit autophagy in lung cancer cells by inhibiting KRAS G12C signaling, thereby inhibiting the proliferation of lung cancer cells and exerting anti-cancer effects .
1
Category:
Human Gut Microbiota Metabolites Microorganisms Neurological Disease Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Inflammation/Immunology
Target:
1
Target:
Forschungsgebiete:
Altiratinib (DCC-2701) is a multi-targeted kinase inhibitor with IC50s of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for MET, TIE2, VEGFR2, FLT3, Trk1, Trk2, and Trk3 respectively.
Synonyms: DCC-3014
Vimseltinib (DCC-3014) is a c-FMS (CSF-IR) and c-Kit dual inhibitor extracted from patent WO2014145025A2, Compound Example 10, has IC50s of <0.01 μM and 0.1-1 μM, respectively . Vimseltinib has certain oral bioavailability .
Art. -Nr.: HY-D2751
CAS. Nr.: 1178534-61-6
Art. -Nr.: HY-W099632
CAS. Nr.: 25354-97-6
Target:
Forschungsgebiete:
2-Hexyldecanoic acid is a lipid containing one carboxylic acid group and two non-polar tails. In the presence of EDC, HATU and DCC, carboxylic acid groups can undergo continuous amide coupling reactions with amine-containing biomolecules to form stable amide bonds. 2-Hexyldecanoic acid can be used as an aerolysin inhibitor to prevent bacterial pathogens. 2-Hexyldecanoic acid can cause contact dermatitis .
Art. -Nr.: HY-W074890R
CAS. Nr.: 2441-41-0
Synonyms: N-palmitoyl glycine (Standard)
Art. -Nr.: HY-112306R
CAS. Nr.: 1442472-39-0
Synonyms: DCC-2618 (Standard)
Ripretinib (Standard) is the analytical standard of Ripretinib. This product is intended for research and analytical applications. Ripretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFRA switch-control inhibitor. Ripretinib (DCC-2618) targets and binds to both wild-type and mutant forms of KIT and PDGFRA specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. Ripretinib (DCC-2618) also inhibits multiple other kinase targets, such as FLT3 and KDR (or VEGFR-2) . DCC-2618 exerts antineoplastic effect and induces apoptosis .
Art. -Nr.: HY-D2772
CAS. Nr.: 383912-87-6
Art. -Nr.: HY-RS03571
Target:
Forschungsgebiete:
DCC Human Pre-designed siRNA Set A contains three designed siRNAs for DCC gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Art. -Nr.: HY-RS23634
Target:
Forschungsgebiete:
Dcc Rat Pre-designed siRNA Set A contains three designed siRNAs for Dcc gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Art. -Nr.: HY-100855
CAS. Nr.: 108181-00-6
Target:
Forschungsgebiete:
DC_C66 is a cell-permeable, selective coactivator associated arginine methyltransferase 1 (CARM1) inhibitor with an IC50 of 1.8 μM. DC_C66 has a good selectivity for CARM1 against PRMT1 (IC50=21 μM), PRMT6 (IC50= 47μM), and PRMT5 .
Art. -Nr.: HY-163008
CAS. Nr.: 2339488-53-6
Target:
Forschungsgebiete:
Dicamba-5-aminopentanoic acid (DCc) is an immunizing and heterologous hapten, designed using the carboxylic acid group of dicamba to introduce a spacer arm for a better exposure of the herbicide's structure .
Art. -Nr.: HY-D2764
CAS. Nr.: 886210-16-8
Art. -Nr.: HY-157262
CAS. Nr.: 2710224-09-0
Methyl isonicotinate-(CH2)2-COOH (hapten 2b) is a hapten that can be activated with NHS and DCC. Methyl isonicotinate-(CH2)2-COOH has more immunogenicity and hydrophobicity .
Art. -Nr.: HY-D2765
CAS. Nr.: 757156-70-0
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
